News
Acquisition · Breast Cancer · Oncology · Pharmaceuticals
Novartis AG (NVS) announced an agreement to acquire a next-generation breast cancer therapy, SNV4818, from Synnovation Therapeutics for an upfront payment of $2 billion and up to $1 billion in milestone payments, totaling up to $3 billion, significantly strengthening its oncology pipeline.
The acquired asset, SNV4818, is a pan-mutant-selective PI3Ka inhibitor currently undergoing a Phase 1/2 study for patients with breast cancer and other advanced solid tumors. This therapy is designed to specifically target cancer-driving mutations while preserving healthy cells, aiming for improved tolerability and more durable treatment outcomes.
According to RTTNews, the transaction involves Novartis acquiring Synnovation's unit, Pikavation Therapeutics, which holds the PI3Ka inhibitor portfolio. The acquisition supports Novartis's strategic focus on hormone receptor-positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer and is expected to finalize in the first half of 2026.
